Bispecific Antibodies for Multiple Myeloma: Pharmacist Insights & Challenges

The treatment of relapsed or refractory multiple myeloma (RRMM) is undergoing a significant shift with the increasing use of bispecific antibodies. These therapies, while promising, present a new set of challenges for healthcare professionals, particularly pharmacists, as they navigate complexities beyond simply assessing efficacy. January 27, 2025, Pharmacy Times reported on these emerging hurdles.

Understanding Bispecific Antibodies in Multiple Myeloma

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell. RRMM refers to the condition when the cancer returns after treatment or doesn’t respond to initial therapies. Bispecific antibodies represent a novel approach to treatment, offering a potential alternative for patients who have exhausted other options. These antibodies are engineered to bind to two different targets: one on the myeloma cells and another on immune cells, such as T cells. This dual action helps to bring the immune cells closer to the cancer cells, enhancing the body’s natural ability to fight the disease.

Currently, three bispecific therapies are available for RRMM: teclistamab, elranatamab, and talquetamab. A review published in PubMed highlights the clinical trial data, safety endpoints, and practical administration considerations for these therapies. The article details the efficacy and safety results observed in trials, as well as the differences in dosing and monitoring requirements for each bispecific antibody.

Real-World Challenges for Pharmacists

The introduction of bispecific antibodies has expanded the role of pharmacists beyond traditional dispensing, and monitoring. They are now integral in managing the unique challenges associated with these therapies. One key concern is the potential for significant side effects, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is an overreaction of the immune system, while ICANS affects the nervous system.

According to reports, while both bispecific treatments can cause CRS and neurotoxicity, bispecific antibodies offer more controlled dosing environments compared to other immunotherapies. However, careful monitoring and management of these adverse events are crucial. The challenges to bispecific integration across practice settings require careful consideration.

Managing Adverse Events

Effective management of adverse events requires a proactive approach. The PubMed review emphasizes the need for antimicrobial prophylaxis, premedication, and, in some cases, intravenous immunoglobulin (IVIG) replacement. Hospitalization may be required, particularly for patients at higher risk of complications or those experiencing severe side effects. Pharmacists play a vital role in ensuring appropriate premedication is administered and in monitoring patients for signs and symptoms of CRS and ICANS.

The review also highlights the importance of understanding the specific dosing and monitoring requirements for each bispecific antibody. Teclistamab, elranatamab, and talquetamab each have unique protocols that pharmacists must be familiar with to ensure optimal patient care.

Practical Considerations for Administration

Beyond managing adverse events, practical considerations for bispecific antibody administration include determining hospitalization requirements, establishing robust monitoring protocols, and addressing medication-related issues. The initial doses of these therapies often require close observation in a hospital setting to manage potential side effects. Ongoing monitoring is essential to assess treatment response and identify any emerging complications.

The evolving landscape of bispecific antibody therapy also necessitates ongoing clinical trials and research. These studies are crucial for refining treatment protocols, identifying new biomarkers for predicting response, and developing strategies to mitigate adverse events. Future directions in this field will likely focus on combining bispecific antibodies with other therapies, such as chemotherapy or stem cell transplantation, to further improve outcomes for patients with RRMM.

The Expanding Role of Pharmacists

The increasing use of bispecific antibodies in RRMM underscores the expanding role of pharmacists in oncology care. Their expertise in medication management, adverse event monitoring, and patient education is essential for ensuring the safe and effective use of these novel therapies. As more bispecific antibodies become available and their use becomes more widespread, pharmacists will continue to be at the forefront of optimizing treatment strategies and improving the lives of patients with multiple myeloma.

The Pharmacy Times Clinical Forum, held during the February 23, 2026 American Society of Hematology Annual Meeting and Exposition, further emphasized the need for ongoing education and collaboration among healthcare professionals to address the real-world challenges of bispecific antibody therapy.